Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
In a nationally representative sample of 734,061 US adults, lifetime psilocybin use was associated with reduced odds of arrests for property crime, assault, serious violence and miscellaneous crimes. However, these protective associations were moderated by race and ethnicity and were not observed for Black and Hispanic participants.
Authors
- George Jones
- Matthew Nock
Published
Abstract
Introduction
Psilocybin use has been linked to lowered odds of crime-related outcomes across a host of observational studies. No studies have investigated how these associations may differ among those of different races and ethnicities.
Methods
Using a nationally-representative sample of 734,061 adults from the National Survey on Drug Use and Health (2002–2020), we investigated whether race and ethnicity moderate the associations between lifetime psilocybin use and four measures of crime arrests (property crime, assault, serious violence, and miscellaneous crimes).
Results
First, we replicated prior findings and demonstrated that psilocybin confers lowered odds of crime arrests for all four outcomes in question. Second, we demonstrated that race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests for three of our four outcomes. Third, we examined the associations between psilocybin and crime arrests across different races and ethnicities (White, Black, Indigenous, Asian, Multiracial, and Hispanic participants). Psilocybin conferred lowered odds of at least one crime arrest outcome for all racial and ethnic groups except for Black and Hispanic participants.
Discussion
Future investigations should take an intersectional approach to studying the interrelationship of sociodemographic factors, psychedelic use, and crime, examine the structural factors (i.e., systemic racism) that may underlie these results, and investigate whether psychedelics can alleviate mental health disorders that contribute to cycles of recriminalization for communities of color.
Research Summary of 'Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests'
Introduction
Psychedelic compounds such as MDMA and psilocybin have attracted considerable research interest because clinical and naturalistic studies suggest they can produce meaningful improvements in mood, social connectedness, and other mental health outcomes. However, most clinical trials to date have enrolled predominantly White participants, limiting generalisability to racial and ethnic minority populations. Population-based survey analyses have previously linked lifetime use of classic psychedelics—psilocybin among them—to lower odds of psychological distress and suicidality, but questions remain about whether these associations vary across racial and ethnic groups. Jones and colleagues set out to test whether race and ethnicity moderate the associations between lifetime MDMA use and psilocybin use and two mental health outcomes: past month serious psychological distress and past year suicidal ideation and planning. Using a large, nationally representative dataset, the study aims to clarify whether previously observed protective associations of these substances apply equally across White, non‑White, and Hispanic populations and to identify areas where further, more targeted research is needed.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Jones, G., Al-Suwaidi, M., Castro-Ramirez, F., McGuire, T. C., Mair, P., & Nock, M. K. (2023). Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1169692
References (21)
Papers cited by this study that are also in Blossom
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Nichols, D. E. · Journal of Antibiotics (2020)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2012)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Weissman, C. R., Zeifman, R. J., Yu, D. et al. · Journal of Clinical Psychiatry (2022)
Show all 21 referencesShow fewer
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Williams, T. M., Davis, A. K., Xin, Y. et al. · Drugs Education Prevention and Policy (2020)
Davis, A. K., Xin, Y., Sepeda, N. D. et al. · Chronic Stress (2021)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Jones, G. M., Nock, M. K. · Journal of Psychopharmacology (2022)
Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)
Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)
Jones, G. M., Nock, M. K. · Scientific Reports (2022)
Argento, E., Strathdee, S. A., Tupper, K. et al. · BMJ Open (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.